NuPathe Inc. (PATH) Files $86.25M IPO

May 14, 2010 1:37 PM EDT Send to a Friend
NuPathe, Inc. (Nasdaq: PATH) filed a registration statement with the U.S. Securities and Exchange Commission today for an Initial Public Offering of its shares. The proposed maximum aggregate offering price is $86.25 million. The company plans to list on the Nasdaq Global Market under the ticker "PATH."

The offering is being made through Leerink Swann, Lazard Capital Markets, Thomas Weisel Partners, and Needham & Company.

NuPathe is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.

You May Also Be Interested In





Related Categories

IPOs

Related Entities

Needham & Company, Lazard, Thomas Weisel Partners Group

Add Your Comment